Critical Therapeutics, Inc. Files Registration Statement on Form S-4 with Securities and Exchange Commission

LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (NASDAQ: CRTX) announced today that it has filed a Registration Statement on Form S-4 with the Securities and Exchange Commission containing the preliminary Proxy Statement/Prospectus in connection with the previously announced merger agreement between Critical Therapeutics and Cornerstone BioPharma Holdings, Inc. (Cornerstone). Cornerstone is a privately-held specialty pharmaceutical company focused on developing and commercializing prescription medications for respiratory disorders.